Baidu
map
ISCIENCE 润色咨询

iScience

出版年份：暂无数据 年文章数：3724 投稿命中率： 开通期刊会员，数据随心看

出版周期：M 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0<br>经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;蛋白组<br>经验分享：2024年2月16投稿<br>2024年3月18小修<br>2024年3月29修回，等得都想催稿了<br>2024年4月24原则性接收，开始改格式，改了三四次格式<br>2024年5月09接收<br>感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：分子生物<br>经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2228305, encodeId=8cb1222830589, content=不知道heliyon on hold对于iScience是利好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sun Sep 29 09:07:48 CST 2024, time=2024-09-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：生态学<br>经验分享：2023年8月投稿<br>2023年11月第一轮 给了大修<br>2024年2月28日修回<br>2024年3月20日pre-accept<br>2024年3月26日格式修改修回<br>2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0<br>经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合<br>经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合<br>经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省)]
    2024-10-16 ms3000001892618058 来自湖北省

    二审两个多月了，还没消息，有一样的小伙伴吗？

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0<br>经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;蛋白组<br>经验分享：2024年2月16投稿<br>2024年3月18小修<br>2024年3月29修回，等得都想催稿了<br>2024年4月24原则性接收，开始改格式，改了三四次格式<br>2024年5月09接收<br>感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：分子生物<br>经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2228305, encodeId=8cb1222830589, content=不知道heliyon on hold对于iScience是利好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sun Sep 29 09:07:48 CST 2024, time=2024-09-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：生态学<br>经验分享：2023年8月投稿<br>2023年11月第一轮 给了大修<br>2024年2月28日修回<br>2024年3月20日pre-accept<br>2024年3月26日格式修改修回<br>2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0<br>经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合<br>经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合<br>经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省)]
    2024-06-03 ms4000001339792170 来自湖北省

    审稿速度:1.0
    经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0<br>经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;蛋白组<br>经验分享：2024年2月16投稿<br>2024年3月18小修<br>2024年3月29修回，等得都想催稿了<br>2024年4月24原则性接收，开始改格式，改了三四次格式<br>2024年5月09接收<br>感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：分子生物<br>经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2228305, encodeId=8cb1222830589, content=不知道heliyon on hold对于iScience是利好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sun Sep 29 09:07:48 CST 2024, time=2024-09-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：生态学<br>经验分享：2023年8月投稿<br>2023年11月第一轮 给了大修<br>2024年2月28日修回<br>2024年3月20日pre-accept<br>2024年3月26日格式修改修回<br>2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0<br>经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合<br>经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合<br>经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省)]
    2024-05-09 ms2000000185262432 来自广西

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤;蛋白组
    经验分享：2024年2月16投稿
    2024年3月18小修
    2024年3月29修回，等得都想催稿了
    2024年4月24原则性接收，开始改格式，改了三四次格式
    2024年5月09接收
    感谢iscience的认可，兄弟们加油

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0<br>经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;蛋白组<br>经验分享：2024年2月16投稿<br>2024年3月18小修<br>2024年3月29修回，等得都想催稿了<br>2024年4月24原则性接收，开始改格式，改了三四次格式<br>2024年5月09接收<br>感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：分子生物<br>经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2228305, encodeId=8cb1222830589, content=不知道heliyon on hold对于iScience是利好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sun Sep 29 09:07:48 CST 2024, time=2024-09-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：生态学<br>经验分享：2023年8月投稿<br>2023年11月第一轮 给了大修<br>2024年2月28日修回<br>2024年3月20日pre-accept<br>2024年3月26日格式修改修回<br>2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0<br>经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合<br>经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合<br>经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省)]
    2024-08-27 ms2000000368944021 来自湖南省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向：分子生物
    经验分享：all reviews complete要多久呀

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0<br>经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;蛋白组<br>经验分享：2024年2月16投稿<br>2024年3月18小修<br>2024年3月29修回，等得都想催稿了<br>2024年4月24原则性接收，开始改格式，改了三四次格式<br>2024年5月09接收<br>感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：分子生物<br>经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2228305, encodeId=8cb1222830589, content=不知道heliyon on hold对于iScience是利好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sun Sep 29 09:07:48 CST 2024, time=2024-09-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：生态学<br>经验分享：2023年8月投稿<br>2023年11月第一轮 给了大修<br>2024年2月28日修回<br>2024年3月20日pre-accept<br>2024年3月26日格式修改修回<br>2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0<br>经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合<br>经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合<br>经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省)]
    2024-09-29 ms3000000851999119 来自北京

    不知道heliyon on hold对于iScience是利好吗

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0<br>经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;蛋白组<br>经验分享：2024年2月16投稿<br>2024年3月18小修<br>2024年3月29修回，等得都想催稿了<br>2024年4月24原则性接收，开始改格式，改了三四次格式<br>2024年5月09接收<br>感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：分子生物<br>经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2228305, encodeId=8cb1222830589, content=不知道heliyon on hold对于iScience是利好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sun Sep 29 09:07:48 CST 2024, time=2024-09-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：生态学<br>经验分享：2023年8月投稿<br>2023年11月第一轮 给了大修<br>2024年2月28日修回<br>2024年3月20日pre-accept<br>2024年3月26日格式修改修回<br>2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0<br>经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合<br>经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合<br>经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省)]
    2024-09-17 ms3000000851999119 来自北京

    感觉这个期刊录用率只有1/8#生信#

    4

    展开4条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0<br>经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;蛋白组<br>经验分享：2024年2月16投稿<br>2024年3月18小修<br>2024年3月29修回，等得都想催稿了<br>2024年4月24原则性接收，开始改格式，改了三四次格式<br>2024年5月09接收<br>感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：分子生物<br>经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2228305, encodeId=8cb1222830589, content=不知道heliyon on hold对于iScience是利好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sun Sep 29 09:07:48 CST 2024, time=2024-09-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：生态学<br>经验分享：2023年8月投稿<br>2023年11月第一轮 给了大修<br>2024年2月28日修回<br>2024年3月20日pre-accept<br>2024年3月26日格式修改修回<br>2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0<br>经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合<br>经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合<br>经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省)]
    2024-04-06 ms6000000307870975 来自北京

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向：生态学
    经验分享：2023年8月投稿
    2023年11月第一轮 给了大修
    2024年2月28日修回
    2024年3月20日pre-accept
    2024年3月26日格式修改修回
    2024年4月1日 with editor。。。

    6

    展开6条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0<br>经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;蛋白组<br>经验分享：2024年2月16投稿<br>2024年3月18小修<br>2024年3月29修回，等得都想催稿了<br>2024年4月24原则性接收，开始改格式，改了三四次格式<br>2024年5月09接收<br>感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：分子生物<br>经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2228305, encodeId=8cb1222830589, content=不知道heliyon on hold对于iScience是利好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sun Sep 29 09:07:48 CST 2024, time=2024-09-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：生态学<br>经验分享：2023年8月投稿<br>2023年11月第一轮 给了大修<br>2024年2月28日修回<br>2024年3月20日pre-accept<br>2024年3月26日格式修改修回<br>2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0<br>经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合<br>经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合<br>经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省)]
    2022-11-01 ms6000000988225388

    审稿速度:6.0
    经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急

    6

    展开6条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0<br>经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;蛋白组<br>经验分享：2024年2月16投稿<br>2024年3月18小修<br>2024年3月29修回，等得都想催稿了<br>2024年4月24原则性接收，开始改格式，改了三四次格式<br>2024年5月09接收<br>感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：分子生物<br>经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2228305, encodeId=8cb1222830589, content=不知道heliyon on hold对于iScience是利好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sun Sep 29 09:07:48 CST 2024, time=2024-09-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：生态学<br>经验分享：2023年8月投稿<br>2023年11月第一轮 给了大修<br>2024年2月28日修回<br>2024年3月20日pre-accept<br>2024年3月26日格式修改修回<br>2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0<br>经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合<br>经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合<br>经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省)]
    2024-08-04 少吃一口 来自四川省

    偏重的研究方向：免疫学;医学综合
    经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2231251, encodeId=7c1722312512e, content=二审两个多月了，还没消息，有一样的小伙伴吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=522b9253477, createdName=ms3000001892618058, createdTime=Wed Oct 16 22:35:58 CST 2024, time=2024-10-16, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0<br>经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2203734, encodeId=33412203e34f5, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;蛋白组<br>经验分享：2024年2月16投稿<br>2024年3月18小修<br>2024年3月29修回，等得都想催稿了<br>2024年4月24原则性接收，开始改格式，改了三四次格式<br>2024年5月09接收<br>感谢iscience的认可，兄弟们加油, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Thu May 09 20:56:44 CST 2024, time=2024-05-09, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向：分子生物<br>经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2228305, encodeId=8cb1222830589, content=不知道heliyon on hold对于iScience是利好吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Sun Sep 29 09:07:48 CST 2024, time=2024-09-29, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=4, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：生态学<br>经验分享：2023年8月投稿<br>2023年11月第一轮 给了大修<br>2024年2月28日修回<br>2024年3月20日pre-accept<br>2024年3月26日格式修改修回<br>2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0<br>经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合<br>经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合<br>经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省)]
    2024-08-03 少吃一口 来自四川省

    偏重的研究方向：免疫学;生物大分子;医学综合
    经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？

    0

共317条页码: 1/32页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map